Will resistance to erdafitinib develop?

Drug resistance is a common treatment challenge that can also occur with the use of targeted therapies such as Erdafitinib. Drug resistance can cause the drug to become ineffective, allowing tumors to start growing again. Drug resistance may develop during use of FGFR inhibitors, including erdafitinib. Some factors that may lead to drug resistance include genetic mutations in cancer cells, variations in signaling pathways, and tumor heterogeneity. In addition, long-term use of drugs may also lead to the development of drug resistance. To slow the development of resistance, doctors may use strategies such as rotating treatments, combining medications, or regular monitoring. Developments in research and clinical practice are also helping to deepen our understanding of drug resistance mechanisms, leading to better optimization of treatment options.